RxDoctor Payments Data

Jeffrey Gartrell, MD

Family Medicine · Omaha, NENPI 1356579148

Payments from drug & device makers

$1,078in general payments, 2019–2025

Across 67 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$243
  • AbbVie$224
  • Amgen$81
  • Bayer$47
  • Sanofi-aventis U.S. LLC$43
  • Lilly USA, LLC$43
  • plus $397 from 17 others

What the payments were for

  • Food & beverage$1,078100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,078 in reported general payments places this provider in the 60th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$93,301
Medicare patients
238
Services billed
1,818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide53$61,924
OzempicSemaglutide50$44,976
JanuviaSitagliptin Phosphate34$28,811
EliquisApixaban16$15,617
LinzessLinaclotide13$12,978
SymbicortBudesonide/Formoterol Fumarate29$12,311
XareltoRivaroxaban13$10,859
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,117
Tresiba Flextouch U-200Insulin Degludec14$6,858
Combivent RespimatIpratropium/Albuterol Sulfate13$6,317
Breo ElliptaFluticasone/Vilanterol13$5,258
LexaproEscitalopram Oxalate12$5,185
Gabapentin181$2,877
Omeprazole160$2,571
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,866

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$43$61,92453 claims
Novo NordiskOzempic$243$44,97650 claims
AbbVieLinzess, Lexapro, Synthroid$224$18,99339 claims
PfizerEliquis$11$15,61716 claims
AstraZenecaSymbicort$39$12,31129 claims
Johnson & JohnsonXarelto$26$10,85913 claims
Boehringer IngelheimCombivent Respimat$13$6,31713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →